The Latest Breaking News from Vinay Prasad

‘I do not work for Big Pharma. I work in support of President Trump on the outside of the administration,’ Loomer tells The Independent

On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage.

Trump administration gives no details about reason for departure of Vinay Prasad, but he had critics and had taken unusual actions

The Food and Drug Administration named a longtime pharmaceutical executive to run the agency’s drug program

Amid Trump cuts and state-level backlash, experts worry that progress in messenger RNA vaccines could stall

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines

Frustration and anger mount as Trump administration contemplates new trials and restrictions for Covid vaccines

On May 27, 2025, Health and Human Services Secretary Robert F. Kennedy Jr. announced that the Centers for Disease Control and Prevention will no longer include the COVID-19 vaccine on the list of immunizations it recommends for healthy children and pregnant women.